A non-clinical comparative study of IL-23 antibodies in psoriasis

Four antibodies that inhibit interleukin (IL)-23 are approved for the treatment of moderate-to-severe plaque psoriasis. Here, we present non-clinical data comparing ustekinumab, guselkumab, tildrakizumab and risankizumab with regard to thermostability, IL-23 binding affinity, inhibitory-binding mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Li, Wang, Yibing, Wan, Qi, Wu, Fei, Barbon, Jeffrey, Dunstan, Robert, Gauld, Stephen, Konrad, Mark, Leys, Laura, McCarthy, Richard, Namovic, Marian, Nelson, Christine, Overmeyer, Gary, Perron, Denise, Su, Zhi, Wang, Leyu, Westmoreland, Susan, Zhang, Jun, Zhu, Rui, Veldman, Geertruida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409790/
https://www.ncbi.nlm.nih.gov/pubmed/34460338
http://dx.doi.org/10.1080/19420862.2021.1964420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409790/
https://www.ncbi.nlm.nih.gov/pubmed/34460338
http://dx.doi.org/10.1080/19420862.2021.1964420

Ejemplares similares